RPS6KA1 and neoplasm: Of note, addition of the RSK inhibitor to a sub-effective concentration of the BRAFV600E/K inhibitor vemurafenib restored tumor control in the BRAFMut melanoma xenograft model (Fig. 3E; Suppl.